Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TMX2-CTNND1 readthrough (nonsense-mediated decay candidate) (TMX2-CTNND1)
- Target
- TMX2-CTNND1
- Molecular classification
- Noncoding RNA, Readthrough transcript, Fusion gene (in cancer when present as a protein-producing fusion)
01
Overview
TMX2-CTNND1 readthrough is a naturally occurring transcript resulting from transcriptional readthrough between the adjacent TMX2 and CTNND1 genes on chromosome 11[3][2][9][4]. This transcript is classified as a candidate for nonsense-mediated decay and, unlike its parental protein-coding genes, does not typically produce a protein. Pathological fusion events involving this locus can disrupt normal cellular function, leading to aberrancies in cell adhesion and signaling pathways that may contribute to oncogenesis[1][5]. However, as a ncRNA, TMX2-CTNND1 itself is neither a receptor nor an enzyme, and is not considered a therapeutic target.
- Other names
- CASCTNND1p120(cas)p120(ctn)Cadherin-associated Src substrateCatenin delta-1p120 cateninTMX2-CTNND1
02
Mechanism of action
Not applicable for the readthrough itself. For pathological fusions (if expressed as protein): Disruption of cell adhesion, signaling, and transcriptional regulation.
03
Biological functions
None directly for TMX2-CTNND1 readthrough (as it is noncoding and primarily targeted for decay)When considering fusion events, potential disruption includes: Aberrant protein interactionsDisrupted cell adhesionAltered cell signalingPromoting oncogenesis (if translated in pathological fusion settings)
04
Disease associations
Cancer (aberrant fusion proteins involving TMX2-CTNND1 and other partners may disrupt regulatory signaling and contribute to oncogenesis)Cleft lip/cleft palateBlepharocheilodontic syndrome 2 (association noted for the locus; likely attributed to regulatory context, not the readthrough specifically)
05
Safety considerations
Not applicable as a therapeutic target.If fusion events are expressed as proteins, potential challenges include loss of essential protein domains and promoting tumorigenesis
06
Interacting drugs
None
07
Biomarkers
None for TMX2-CTNND1 readthrough itselfPossible use for fusion transcript detection in cancer diagnostics (e.g., fusion gene markers in specific tumor types)
Beyond the preview
Go deeper on TMX2-CTNND1 readthrough (nonsense-mediated decay candidate) (TMX2-CTNND1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMX2-CTNND1 readthrough (nonsense-mediated decay candidate) (TMX2-CTNND1).